Mechanism of bone marrow-derived mesenchymal stem cells in the treatment of liver failure

doi:10.16352/j.issn.1001-6325.2024.11.1608

Abstract

Abstract: Liver failure is a kind of acute and severe liver disease. Bone marrow-derived mesenchymal stem cells (BM-MSCs) have the function of differentiating into hepatocytes. Promotion of the regeneration of hepatocytes regeneration, inhibition of apoptosis, necrosis and inflammation of hepatocytes, may facilitate repairing damaged liver tissue and improving liver function. BM-MSCs have become a new choice with great application potential in the treatment of liver failure.

Key words: liver failure, mesenchymal stem cell, regeneration, transplantation

CLC Number:

R575.3

QI Zeqiang, GUO Tingyu, WU Zhinian, WANG Yadong. Mechanism of bone marrow-derived mesenchymal stem cells in the treatment of liver failure[J]. Basic & Clinical Medicine, 2024, 44(11): 1608-1612.

References

[1] Wesley BT, Ross ADB, Muraro D, et al. Single-cell atlas of human liver development reveals pathways directing hepatic cell fates[J]. Nat Cell Biol, 2022, 24: 1487-1498. doi:10.1038/s41556-022-00989-7.
[2] Purwaningrum M, Jamilah NS, Purbantoro SD, et al. Comparative characteristic study from bone marrow-derived mesenchymal stem cells[J]. J Vet Sci, 2021, 22: e74. doi:10.4142/jvs.2021.22.e74.
[3] Petrenko Y, Vackova I, Kekulova K, et al. A compara-tive analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential[J]. Sci Rep, 2020, 10: 4290. doi:10.1038/s41598-020-61167-z.
[4] Wang H, Yao W, Wang Y, et al. Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure[J]. Stem Cell Res Ther, 2023, 14: 267. doi: 10.1186/s13287-023-03494-2.
[5] Schacher FC, Martins Pezzi da Silva A, Silla L, et al. Bone marrow mesenchymal stem cells in acute-on-chronic liver failure grades 2 and 3: a phase I-II randomized clinical trial[J]. Can J Gastroenterol Hepatol, 2021, 2021: 3662776. doi:10.1155/2021/3662776.
[6] Aithal AP, Bairy LK, Seetharam RN, et al. Hepatoprotective effect of bone marrow-derived mesenchymal stromal cells in CCl(4)-induced liver cirrhosis[J]. 3 Biotech, 2021, 11: 107. doi:10.1007/s13205-021-02640-y.
[7] Shi H, Wang X, Li F, et al. CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis[J]. Sci Transl Med, 2022, 14: eabp8309. doi:10.1126/scitranslmed.abp8309.
[8] Sheng M, Lin Y, Xu D, et al. CD47-mediated hedgehog/SMO/GLI1 signaling promotes mesenchymal stem cell immunomodulation in mouse liver inflammation[J]. Hepatology, 2021, 74: 1560-1577. doi:10.1002/hep.31831.
[9] Garg A, Khan S, Luu N, et al. TGFβ1 priming enhances CXCR3-mediated mesenchymal stromal cell engraftment to the liver and enhances anti-inflammatory efficacy[J]. J Cell Mol Med, 2023, 27: 864-878. doi:10.1111/jcmm.17698.
[10] Li C, Jin Y, Wei S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J]. Hepatology, 2019, 70: 1714-1731. doi:10.1002/hep.30700.
[11] Watanabe Y, Fukuda T, Hayashi C, et al. Extracellular vesicles derived from GMSCs stimulated with TNF-α and IFN-α promote M2 macrophage polarization via enhanced CD73 and CD5L expression[J]. Sci Rep, 2022, 12: 13344. doi:10.1038/s41598-022-17692-0.
[12] Wan YM, Li ZQ, Zhou Q, et al. Mesenchymal stem cells alleviate liver injury induced by chronic-binge ethanol feeding in mice via release of TSG6 and suppression of STAT3 activation[J]. Stem Cell Res Ther, 2020, 11: 24. doi:10.1186/s13287-019-1547-8.
[13] Kulesza A, Paczek L, Burdzinska A. The role of COX-2 and PGE2 in the regulation of immunomodulation and other functions of mesenchymal stromal cells[J]. Biomedicines, 2023, 11. doi:10.3390/biomedicines11020445.
[14] Zhang Y, Zhangdi H, Nie X, et al. Exosomes derived from BMMSCs mitigate the hepatic fibrosis via anti-pyroptosis pathway in a cirrhosis model[J]. Cells, 2022, 11. doi:10.3390/cells11244004.
[15] Luo XY, Meng XJ, Cao DC, et al. Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes[J]. Stem Cell Res Ther, 2019, 10: 16. doi:10.1186/s13287-018-1122-8.
[16] Li YH, Shen S, Shao T, et al. Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6C(hi/lo) macrophages through activating the cytokine-paracrine and apoptotic pathways[J]. Cell Death Discov, 2021, 7: 239. doi:10.1038/s41420-021-00584-z.
[17] Ma L, Wei J, Zeng Y, et al. Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J]. Drug Deliv, 2022, 29: 440-453. doi:10.1080/10717544.2022.2030428.
[18] Takeuchi S, Tsuchiya A, Iwasawa T, et al. Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis[J]. NPJ Regen Med, 2021, 6: 19. doi:10.1038/s41536-021-00132-4.
[19] Xu J, Chen P, Yu C, et al. Hypoxic bone marrow mesenchymal stromal cells-derived exosomal miR-182-5p promotes liver regeneration via FOXO1-mediated macrophage polarization[J]. FASEB J, 2022, 36: e22553. doi:10.1096/fj.202101868RRR.
[20] Zhang J, Gao J, Li X, et al. Bone marrow mesenchymal stem cell-derived small extracellular vesicles promote liver regeneration via miR-20a-5p/PTEN[J]. Front Pharmacol, 2023, 14: 1168545. doi:10.3389/fphar.2023.1168545.
[21] Lin D, Chen H, Xiong J, et al. Mesenchymal stem cells exosomal let-7a-5p improve autophagic flux and alleviate liver injury in acute-on-chronic liver failure by promoting nuclear expression of TFEB[J]. Cell Death Dis, 2022, 13: 865. doi:10.1038/s41419-022-05303-9.
[22] Heo SK, Yu HM, Kim DK, et al. LIGHT (TNFSF14) promotes the differentiation of human bone marrow-derived mesenchymal stem cells into functional hepatocyte-like cells[J]. PLoS One, 2023, 18: e0289798. doi:10.1371/journal.pone.0289798.
[23] Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial[J]. Hepatology, 2017, 66: 209-219. doi:10.1002/hep.29189.
[24] Casiraghi F, Perico N, Podestà MA, et al. Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: a randomized controlled trial[J]. Am J Transplant, 2021, 21: 2795-2809. doi:10.1111/ajt.16468.
[25] Zhang Y, Zhang J, Yi H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase Ⅰ/Ⅱ randomized, open-label, controlled trial[J]. Stem Cell Res Ther, 2021, 12: 244. doi:10.1186/s13287-021-02246-4.